• 1
    Stephenson RA. Prostate cancer trends in the era of prostate-specific antigen. An update of incidence, mortality, and clinical factors from the SEER database. Urol Clin North Am. 2002; 29: 173181.
  • 2
    Bhatnagar V, Stewart ST, Huynh V, Jorgensen G, Kaplan RM. Estimating the risk of long-term erectile, urinary and bowel symptoms resulting from prostate cancer treatment. Prostate Cancer Prostatic Dis. 2006; 9: 136146.
  • 3
    Bostwick DG. Practical clinical application of predictive factors in prostate cancer. A review with an emphasis on quantitative methods in tissue specimens. Anal Quant Cytol Histol. 1998; 20: 323342.
  • 4
    Blute ML, Bergstralh EJ, Partin AW, et al. Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. J Urol. 2000; 164: 15911595.
  • 5
    Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology. 2001; 58: 843848.
  • 6
    Partin AW, Yoo J, Carter HB, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 1993; 150: 110114.
  • 7
    Gleason DF. Classification of prostatic carcinomas. Cancer Chemother Rep. 1966; 50: 125128.
  • 8
    Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA. 1998; 280: 975980. Comment in: JAMA. 1998;280:1008–1010.
  • 9
    Walling HW, Fosko SW, Geraminejad PA, Whitaker DC, Arpey CJ. Aggressive basal cell carcinoma: presentation, pathogenesis, and management. Cancer Metastasis Rev. 2004; 23: 389402.
  • 10
    Villers A, McNeal JE, Redwine EA, Freiha FS, Stamey TA. The role of perineural space invasion in the local spread of prostatic adenocarcinoma. J Urol. 1989; 142: 763768.
  • 11
    Powell MS, Li R, Dai H, Sayeeduddin M, Wheeler TM, Ayala GE. Neuroanatomy of the normal prostate. Prostate. 2005; 65: 5257.
  • 12
    Ayala GE, Dai H, Ittmann M, et al. Growth and survival mechanisms associated with perineural invasion in prostate cancer. Cancer Res. 2004; 64: 60826090.
  • 13
    Rubin MA, Bismar TA, Curtis S, Montie JE. Prostate needle biopsy reporting: How are the surgical members of the society of urologic oncology using pathology reports to guide treatment of prostate cancer patients? Am J Surg Pathol. 2004; 28: 946952.
  • 14
    Minardi D, Galosi AB, Dell'Atti L, Yehia M, Muzzonigro G. Detectable serum PSA after radical prostatectomy. Clinical and pathological relevance of perianastomotic biopsies. Anticancer Res. 2004; 24: 11791185.
  • 15
    Kramer NM, Hanlon AL, Horwitz EM, Pinover WH, Hanks GH. Biochemical failure rates in prostate cancer patients predicted to have biologically insignificant tumors treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys. 2002; 53: 277281.
  • 16
    D'Amico AV, Wu Y, Chen MH, Nash M, Renshaw AA, Richie JP. Perineural invasion as a predictor of biochemical outcome following radical prostatectomy for select men with clinically localized prostate cancer. J Urol. 2001; 165: 126129.
  • 17
    de la Taille A, Rubin MA, Bagiella E, et al. Can perineural invasion on prostate needle biopsy predict prostate specific antigen recurrence after radical prostatectomy? J Urol. 1999; 162: 103106.
  • 18
    Freedland SJ, Csathy GS, Dorey F, Aronson WJ. Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score. J Urol. 2002; 167: 516520.
  • 19
    Henke RP, Hammerer P, Graefen M, et al. Interphase cytogenetic study of preoperative core biopsies for the prediction of early serum prostate specific antigen recurrence after radical prostatectomy of clinically localized prostate carcinoma. Cancer. 1998; 83: 977988.
  • 20
    Nelson CP, Rubin MA, Strawderman M, Montie JE, Sanda MG. Preoperative parameters for predicting early prostate cancer recurrence after radical prostatectomy. Urology. 2002; 59: 740745.
  • 21
    Nelson CP, Dunn RL, Wei JT, Rubin MA, Montie JE, Sanda MG. Contemporary preoperative parameters predict cancer-free survival after radical prostatectomy: A tool to facilitate treatment decisions. Urologic Oncol. 2003; 21: 213218.
  • 22
    O'Malley KJ, Pound CR, Walsh PC, Epstein JI, Partin AW. Influence of biopsy perineural invasion on long-term biochemical disease-free survival after radical prostatectomy. Urology. 2002; 59: 8590.
  • 23
    Quinn DI, Henshall SM, Brenner PC, et al. Prognostic significance of preoperative factors in localized prostate carcinoma treated with radical prostatectomy: importance of percentage of biopsies that contain tumor and the presence of biopsy perineural invasion. Cancer. 2003; 97: 18841893.
  • 24
    Ravery V, Boccon-Gibod LA, Dauge-Geffroy MC, et al. Systematic biopsies accurately predict extracapsular extension of prostate cancer and persistent/recurrent detectable PSA after radical prostatectomy. Urology. 1994; 44: 371376.
  • 25
    Sebo TJ, Cheville JC, Riehle DL, et al. Perineural invasion and MIB-1 positivity in addition to Gleason score are significant preoperative predictors of progression after radical retropubic prostatectomy for prostate cancer. Am J Surg Pathol. 2002; 26: 431439.
  • 26
    Algan O, Pinover WH, Hanlon AL, Al-Saleem TI, Hanks GE. Is there a subset of patients with PSA > or = 20 ng/mL who do well after conformal beam radiotherapy? Radiat Oncol Investig. 1999; 7: 106110.
  • 27
    Anderson PR, Hanlon AL, Patchefsky A, Al-Saleem T, Hanks GE. Perineural invasion and Gleason 7–10 tumors predict increased failure in prostate cancer patients with pretreatment PSA <10 ng/mL treated with conformal external beam radiation therapy. Int J Radiat Oncol Biol Phys. 1998; 41: 10871092.
  • 28
    Beard CJ, Chen MH, Cote K, et al. Perineural invasion is associated with increased relapse after external beam radiotherapy for men with low-risk prostate cancer and may be a marker for occult, high-grade cancer. Int J Radiat Oncol Biol Phys. 2004; 58: 1924.
  • 29
    Bonin SR, Hanlon AL, Lee WR, Movsas B, al-Saleem TI, Hanks GE. Evidence of increased failure in the treatment of prostate carcinoma patients who have perineural invasion treated with three-dimensional conformal radiation therapy. Cancer. 1997; 79: 7580.
  • 30
    Grann A, Gaudin PB, Raben A, Wallner K. Pathologic features from prostate needle biopsy and prognosis after I-125 brachytherapy. Radiat Oncol Invest. 1998; 6: 170174.
  • 31
    Kaminski JM, Hanlon AL, Horwitz EM, Pinover WH, Mitra RK, Hanks GE. Relationship between prostate volume, prostate-specific antigen nadir, and biochemical control. Int J Radiat Oncol Biol Phys. 2002; 52: 888892.
  • 32
    Kestin LL, Goldstein NS, Vicini FA, Martinez AA. Percentage of positive biopsy cores as predictor of clinical outcome in prostate cancer treated with radiotherapy. J Urol. 2002; 168: 19941999.
  • 33
    Merrick GS, Butler WM, Galbreath RW, Lief JH, Adamovich E. Perineural invasion is not predictive of biochemical outcome following prostate brachytherapy. Cancer J. 2001; 7: 404412.
  • 34
    Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen ZA, Adamovich E. Prognostic significance of perineural invasion on biochemical progression-free survival after prostate brachytherapy. Urology. 2005; 66: 10481053.
  • 35
    Pollack A, Hanlon AL, Horwitz EM, Feigenberg SJ, Uzzo RG, Hanks GE. Prostate cancer radiotherapy dose response: an update of the fox chase experience. J Urol. 2004; 171: 11321136.
  • 36
    Wong WW, Schild SE, Vora SA, Halyard MY. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2004; 60: 2429.
  • 37
    Bossuyt PM, Reitsma JB, Bruns DE, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD Initiative. Ann Intern Med. 2003; 138: 4044.
  • 38
    McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol. 2005; 23: 90679072.
  • 39
    SobinLH, Wittekind, Ch, eds. TNM classification of malignant tumors. 6th ed. New York: Wiley-Liss; 2002.
  • 40
    Gospodarowicz MK, Miller D, Groome PA, Greene FL, Logan PA, Sobin LH. The process for continuous improvement of the TNM classification. Cancer. 2004; 100: 15.
  • 41
    Bismar TA, Lewis JS,Jr., Vollmer RT, Humphrey PA. Multiple measures of carcinoma extent versus perineural invasion in prostate needle biopsy tissue in prediction of pathologic stage in a screening population. Am J Surg Pathol. 2003; 27: 432440.
  • 42
    Lane RB,Jr., Lane CG, Mangold KA, Johnson MH, Allsbrook WC,Jr. Needle biopsies of the prostate: what constitutes adequate histologic sampling? Arch Pathol Lab Med. 1998; 122: 833835.
  • 43
    Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999; 281: 15911597.
  • 44
    Kattan MW, Hess KR, Beck JR. Experiments to determine whether recursive partitioning (CART) or an artificial neural network overcomes theoretical limitations of Cox proportional hazards regression. Comput Biomed Res. 1998; 31: 363373.
  • 45
    McShane LM, Altman DG, Sauerbrei W. Identification of clinically useful cancer prognostic factors: what are we missing? J Natl Cancer Inst. 2005; 97: 10231025.